Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239703 · ClinicalTrials.gov registry record
Trifecta-Kidney cfDNA-MMDx Study
A clinical trial of Kidney Transplant Rejection, sponsored by University of Alberta.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT04239703 is a study of Kidney Transplant Rejection that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 300 participants, below the 768-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04239703, a study of Kidney Transplant Rejection, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prospera
- DIAGNOSTIC_TEST HLA antibody
- DIAGNOSTIC_TEST MMDx
Study Locations (20)
Other
- Department of Nephrology, The Royal Melbourne Hospital 1 South East - Melbourne
- University Hospital Merkur Renal Division - Zagreb
- Institute for Clinical and Experimental Medicine (IKEM) - Prague
- Charite-Medical University of Berlin Department of Nephrology - Berlin
- Centre of Nephrology, Vilnius University Hospital Santaros Klinikos - Vilnius
- Department of Nephrology and Transplantation Medical University in Bialystok - Bialystok
- University Hospital nr1 Bydgoszcz, Klinika Transplantologii - Bydgoszcz
Maryland
- University of Maryland School of Medicine - Baltimore
- The Johns Hopkins University, School of Medicine - Baltimore
Michigan
- Detroit Medical Center, Harper University Hospital of Wayne State University - Detroit
- Henry Ford Hospital - Detroit
Ohio
- University Hospitals Cleveland Medical Ctr. - Cleveland
- Cleveland Clinic - Cleveland
Florida
- Tampa General Hospital - Tampa
Missouri
- Barnes-Jewish Hospital, Washington University at St. Louis - St Louis
Utah
- Intermountain Transplant Services - Murray
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-12-01 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04239703
The ClinicalTrials.gov registry entry for NCT04239703 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 768-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (61% lower). The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant Rejection appearing as the primary indexed condition, and to 3 interventions - of which Prospera is the first listed.
NCT04239703 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT04239703 about?
NCT04239703 is a clinical study titled "Trifecta-Kidney cfDNA-MMDx Study". Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
What is the current status of trial NCT04239703?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-12-01. Estimated completion is 2027-12.
What conditions does trial NCT04239703 study?
This clinical trial studies the following conditions: Kidney Transplant Rejection.
What interventions are being tested in trial NCT04239703?
The interventions under investigation include: Prospera (DIAGNOSTIC_TEST), HLA antibody (DIAGNOSTIC_TEST), MMDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04239703?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04239703 being conducted?
This trial has 20 study locations across Florida, Maryland, Michigan, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
RECRUITING
-
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
RECRUITING
-
Microbiome and Immunosuppression: The Mission Study
ACTIVE NOT RECRUITING
-
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
ACTIVE NOT RECRUITING
-
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection
ACTIVE NOT RECRUITING
-
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.